Symetis' second-gen TAVI device shows positive trial results

04/5/2013 | MassDevice.com (Boston)

Symetis' Acurate TA device, a second-generation transcatheter aortic valve implant already approved in Europe, showed a 98% rate of procedural success and minimal valve leakage in a 250-patient clinical study. The device also showed a 6.8% all-cause mortality rate at 30 days, which the company said was one of the lowest rates reported for TAVI devices.

View Full Article in:

MassDevice.com (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN